Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Collet, J.-P.
Right arrow Articles by Montalescot, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Collet, J.-P.
Right arrow Articles by Montalescot, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Premature withdrawal and alternative therapies to dual oral antiplatelet therapy

Jean-Philippe Collet* and Gilles Montalescot

Institut de Cardiologie Hôpital Pitié-Salpêtrière, 47 bvd de l'Hôpital, 75013 Paris, France

* Corresponding author. Tel: +33 01 42 16 30 13; fax: +33 01 42 16 29 31. E-mail address: Jean-philippe.collet{at}psl.ap-hop-paris.fr

Premature interruption of dual oral antiplatelet therapy is an issue of increasing importance, and is particularly critical for at least three major reasons. First, patients eligible for temporary dual oral antiplatelet therapy are at high risk of acute recurrent thrombosis because they underwent a recent drug-eluting stent implantation or they experienced a recent acute coronary syndrome. Secondly, the proportion of these patients is now increasing and definite guidelines on how to manage interruption do not exist. Lastly, there is now evidence that premature interruption of oral antiplatelet therapy can lead to recurrence of events, with a significant impact on outcome in these high-risk patients. A perceived risk of increased bleeding events often leads to the interruption of oral antiplatelet therapy, but in many instances, the interruption is unjustified. Whether premature interruption of oral antiplatelet therapy is appropriate, and whether alternative therapies should be substituted are two important questions that, to date, remain unresolved. It is unlikely that the issue of premature withdrawal of dual oral antiplatelet therapy in high bleeding risk situations will ever be solved by randomized studies. Indeed, there is an urgent need to define an evidence-based strategy for the management of oral antiplatelet therapy in the peri-operative period. The risks of bleeding and ischaemic events, and the need to interrupt oral antiplatelet therapy, need to be evaluated for common situations such as dental care, or fibroscopic examination of the digestive tract.

Key Words: Antiplatelet agent • Aspirin • Acute coronary syndrome • Stroke • Atherothrombosis • Thrombosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: II. Perioperative Considerations and Management
Anesth. Analg., August 1, 2008; 107(2): 570 - 590.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.